[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nad-levels-in-the-blood\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nad-levels-in-the-blood":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100603152","comparison-of-two-qualia-nad-formulations-on-intracellular-nad-levels-100603152",false,"NCT07132801","Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels","Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels: A Randomized, Double-Blind, Placebo-Controlled Three-Arm Trial","Inclusion Criteria:\n\nProvide voluntary, written, informed consent to participate in the study Agree to provide a valid cell phone number and are willing to receive communications through text Can read and write English Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly Willing to complete questionnaires, records, and diaries associated with the study.\n\nHealthy male and female participants aged 35-75 years Willing to self-administer the intracellular NAD⁺ finger-stick test at home (baseline and Day 28) Willing to avoid supplements, energy drinks\u002Fshots, or other products containing niacin, niacinamide, nicotinamide riboside, or NMN for ≥ 2 weeks before baseline and throughout the study\n\nExclusion Criteria:\n\nWomen who are pregnant, breastfeeding, or planning to become pregnant during the trial Known food intolerances\u002Fallergy to any ingredients in the product Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer Having had a significant cardiovascular event in the past 6 months Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines On immunosuppressive therapy Individuals who were deemed incompatible with the test protocol Adults lacking capacity to consent",true,"ALL","35 Years","75 Years",{"count":21,"type":22},180,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is a randomized, double-blind, placebo-controlled, parallel-group study evaluating the effects of two distinct Qualia NAD⁺ formulations on intracellular NAD⁺ levels in healthy adults aged 35-75 years. Approximately 180 participants will be randomized to one of three study arms: Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, or placebo. Each participant will take two capsules of their assigned product once daily in the morning, with or without food, over a 28-day period. The primary outcome is the change in intracellular NAD⁺ levels, assessed via at-home finger-stick blood collection at baseline and study completion. Secondary endpoints include changes in aging-related symptoms (AMFS scores), health-related quality of life (RAND SF-36), and evaluation of safety and tolerability. All assessments, including electronic questionnaires, are completed remotely without in-person visits.",[28,29],"NAD","NAD+ Levels in the Blood",[31,28],"NAD Supplementation","NOT_YET_RECRUITING","2025-08-13",{"date":35,"type":36},"2025-08-20","ACTUAL",{"date":38,"type":22},"2025-10-13",{"date":40,"type":22},"2025-12-15",{"name":42,"class":43},"Qualia Life Sciences","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":16,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":44},"100554967","effectiveness-of-qualia-nad-supplementation-on-intracellular-nad-levels-100554967","NCT06505967","Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels","Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels: A Randomized Double-Blind Parallel Trial","Inclusion criteria:\n\nProvide voluntary, written, informed consent to participate in the study Agree to provide a valid cell phone number and are willing to receive communications through text.\n\nHealthy male and female participants between the ages of 40-65 years of age. Willingness to complete questionnaires, records, and diaries associated with the study.\n\nWilling to not consume any supplements, energy drinks\u002Fshots, or other products containing any form of supplemental vitamin B3 (e.g., niacin, niacinamide, nicotinamide ribosome, NMN) starting about 2 weeks prior to the baseline NAD fingerstick test and continuing through the intervention period.\n\nWilling to not begin taking any new supplements during the study period, and to continue taking any supplements they are currently using regularly (with the exception of vitamin B3 containing supplements).\n\nWillingness to self-administer the intracellular NAD fingerstick test kit at home for both a baseline and post-intervention blood sample, and to complete a release form that gives researchers access to the results of these tests.\n\nExclusion criteria:\n\nWomen who are pregnant, breastfeeding, or planning to become pregnant during the trial Known food intolerances\u002Fallergy to any ingredients in the product Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer Having had a significant cardiovascular event in the past 6 months Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines On immunosuppressive therapy Individuals who were deemed incompatible with the test protocol Adults lacking capacity to consent","40 Years","65 Years",{"count":55,"type":22},200,[25],"The goal of this clinical trial is to determine if Qualia NAD+ effectively increases NAD+ levels in the blood and to evaluate its safety.\n\nResearchers will compare Qualia NAD+ to a placebo (a look-alike substance that contains no active drug) to assess its efficacy in increasing NAD+ levels in the blood.\n\nParticipants will:\n\nTake Qualia NAD+ or a placebo every day for 4 weeks. Undergo blood tests before and after the trial.",[29],"RECRUITING","2024-07-11",{"date":62,"type":36},"2024-07-17",{"date":64,"type":36},"2024-06-10",{"date":66,"type":22},"2024-09-09",{"name":42,"class":43}]